- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02170545
CT Imaging Evaluation of Humerus Fractures
Computed Tomography Evaluation of Humeral Head Perfusion in Displaced Proximal Humerus Fractures in Predicting Rates of Avascular Necrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current surgical treatment of humeral head fracture does not follow a universally accepted treatment algorithm. Treatment guidelines are lacking sufficient prospective controlled evidence to support any one option as doctrine. However, the generally accepted dogma regarding the surgical treatment of fractures considered high-risk for Avascular Necrosis (AVN), and also symptomatic avascular necrosis of the humeral head, is shoulder replacement (arthroplasty). This is a difficult scenario for younger patients where humeral head preservation is the priority, because of a expected lifespan that will require one, if not multiple, arthroplasty revisions. There is data suggesting no difference in functional outcome for complx humeral head fractures treated with open reduction and internal fixation (ORIF), that late progress to AVN, and patients who undergo hemi-arthroplasty, because of risk of AVN. However, failure of surgery related to AVN remains a challenging problem often leading to secondary surgery, which is not without negative outcomes. This study is aimed at trying to come up with a predictor that can be applied to patients prior to initial humeral head fracture treatment.
The specific aims of the study to help determine this predictor are:
- In patients who have humeral head fracture, evaluate the difference in fracture fragment enhancement in multi-part fractures, by comparing the fracture fragment attenuation on iodine map overlay to the non-traumatized, contralateral humeral head using Dual Energy Computed Tomography (DECT).
- In patients undergoing ORIF or joint replacement for humeral head fracture without known risk factors for AVN, identify the relationship between the attenuation due to iodine in the fractured humeral head, as measured preoperatively by DECT, with the presence of pulsatile blood flow in the humeral head intra-operatively, as measured with laser doppler.
- In patients undergoing joint replacement for humeral head fracture without other known risk factors for AVN, identify the relationship between the attenuation due to iodine in the fractured humeral head, as measured preoperatively by DECT, with the presence of AVN in humeral head pathology specimen.
- In patients who underwent ORIF for humeral head fracture without other known risk factors for AVN, identify the relationship between the attenuation due to iodine within the fractured humeral head, as measured preoperatively by DECT, with the incidence of radiographically apparent AVN after 2 years of clinical follow-up.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with multi-part fracture of proximal humerus.
Exclusion Criteria:
- Patients with a humeral head prosthesis, hardware or avascular necrosis in the ipsilateral shoulder.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Multi-Part Proximal Humerus Fracture
All participants that meet the entry criteria will be included in the study cohort.
|
A Dual Energy Computed Tomography scan will be performed on both upper arms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evidence of avascular necrosis post humeral head fracture.
Time Frame: Within 2 years of fracture correction or surgery.
|
All patients who have humeral head fractures will have a dual energy CT examination performed with intravenous contrast to evaluate the fracture pattern to determine if the patient is a surgical candidate.
The amount of contrast within the fractured humeral head will be measured on this CT scan as a surrogate for blood flow.
After conservative (no surgery) or surgical (open reduction internal fixation) treatment, the patient will be followed in the orthopedics clinic for two years.
During each twice yearly visit, shoulder radiographs will be obtained.
Standardized criteria for radiograph assessment to determine AVN will be used: mixed lucent and sclerotic appearance of the humeral head, subchondral collapse as indicated by a "crescent sign" and/or loss of humeral head sphericity.
AVN will be described as present or absent based on the radiographic findings.
The incidence of AVN will be correlated with the amount of contrast within the humeral head as measured by dual energy CT.
|
Within 2 years of fracture correction or surgery.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin Hoover, MD, PhD, Virginia Commonwealth University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM20000037
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Avascular Necrosis
-
The Hospital for Sick ChildrenTerminatedFemoral Head Avascular NecrosisCanada
-
Universidad Autonoma de MadridCompletedAvascular Necrosis of the Femoral HeadItaly, France, Germany, Spain
-
Guangdong Provincial People's HospitalUnknownAvascular Necrosis of Femur Head
-
University Hospital, Basel, SwitzerlandWithdrawnAvascular Necrosis of the Femoral Head
-
R-BioSMG-SNU Boramae Medical CenterCompletedAvascular Necrosis of the Femoral HeadKorea, Republic of
-
Pei-Yuan Lee, MDAeon Biotechnology CorporationUnknownBone Marrow | Avascular Necrosis of FemurTaiwan
-
Zimmer BiometActive, not recruitingOsteoarthritis, Hip | Avascular Necrosis of Hip | Post-traumatic; Arthrosis | Avascular Necrosis of the Femoral HeadNetherlands, United States, Denmark, Japan, Norway, Sweden
-
The First Affiliated Hospital of Xinxiang Medical...RecruitingAvascular Necrosis of Femur HeadChina
-
Zimmer BiometCompletedArthritis | Avascular NecrosisBelgium
-
Zimmer BiometAarhus University HospitalCompletedArthritis | Avascular NecrosisDenmark
Clinical Trials on Dual Energy Computed Tomography
-
Odense University HospitalUnknownRectal CancerDenmark
-
University of California, Los AngelesCompletedDental DiseasesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
Duke UniversitySiemens Medical SolutionsTerminatedProstate Cancer | Dual Energy CT (DECT)United States
-
M.D. Anderson Cancer CenterActive, not recruitingCarcinoid Tumor | Carcinoid Syndrome | Metastatic Carcinoid Tumor | Digestive System Neuroendocrine Tumor G1United States
-
Medical University of GrazLudwig Boltzmann GesellschaftCompletedPulmonary Arterial HypertensionAustria
-
Medical University of GrazLudwig Boltzmann GesellschaftCompletedPulmonary Arterial HypertensionAustria
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedMalignant Neoplasm | Metastatic Malignant Neoplasm to the BoneUnited States
-
Assistance Publique - Hôpitaux de ParisCanon Medical Systems, USARecruiting
-
Assistance Publique - Hôpitaux de ParisCanon U.S.A., Inc.Active, not recruiting